A review of the pharmacokinetic properties and efficacy of five newer antiarrhythmic agents for treating ventricular arrhythmias.
May inform antiarrhythmic selection in ventricular arrhythmias; leaves open the need for comparative trials.
PreviewThe decision to initiate long-term treatment of ventricular arrhythmias has always been difficult because of the substantial morbidity produced by many drugs and the potential for inducing proarrhythmia. Five recently introduced antiarrhythmic agents promise to enhance the physician's chances of prescribing effective therapy. In this article, the authors review the pharmacokinetic properties and efficacy of these newer agents and offer a clinical perspective on their use.
No takes yet. Share an insight, caveat, or question.
Skluth et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: